Endo International

Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program

Retrieved on: 
Lunedì, Aprile 17, 2023
Senior, Endo International, Fluphenazine, USP, Hospital, Adrenaline, OTC, Endo, FDA, Pharmaceutical industry

DUBLIN, April 17, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping argatroban injection to healthcare providers through Premier's Premier ProRx® private-label program, a guaranteed supply for hospitals and health systems.

Key Points: 
  • DUBLIN, April 17, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping argatroban injection to healthcare providers through Premier's Premier ProRx® private-label program, a guaranteed supply for hospitals and health systems.
  • Argatroban is on FDA's essential medications list and has experienced intermittent supply issues in the broader market.
  • "We're proud to now provide a third product through the reliable Premier ProRx® supply channel."
  • Endo also supplies its Adrenalin® (epinephrine injection, USP), Vasostrict® (vasopressin injection, USP) and fluphenazine decanoate injection, USP products to Premier's hospital customers through the Premier ProRx® private-label program.

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

Retrieved on: 
Venerdì, Marzo 31, 2023
Pfizer, BioCryst Pharmaceuticals, Illinois Wesleyan University, Endo International, Physiology, Research, Vanderbilt University, Doctor of Philosophy, Science, Bachelor of Arts in Organizational Psychology, RESEARCH, Patient, R, Rare, PARK, Management

RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately.
  • He was a model of effective board leadership for us.
  • Our board is comprised of exceptional people with diverse experience and I am excited to continue working alongside them and the management team to deliver innovative new therapies to patients with rare diseases,” said Dr. Hutson.
  • Dr. Hutson was appointed to the board in January 2012, bringing over 30 years of experience as a seasoned professional and leader within the pharmaceutical industry.

Biote Names John Denne as General Manager, Men’s Health Division

Retrieved on: 
Lunedì, Aprile 10, 2023
Biotechnology, General Health, Health, Auxilium, Male, Trade, Hormone replacement therapy, Roche, Marketing, Endo International, Denne, Environmental Health Divisions, Bristol, Growth, Bristol Myers Squibb, Commercial, Pharmaceutical industry, Jacques Biot

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that John Denne has joined the Company as General Manager, Men’s Health Division.

Key Points: 
  • Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that John Denne has joined the Company as General Manager, Men’s Health Division.
  • In this role, Denne will lead Biote’s sales initiatives to expand the Company’s presence in the growing market for male hormone replacement therapy.
  • A healthcare industry veteran, Denne joins Biote with more than 30 years of experience in sales, business development, strategic marketing and management.
  • “We’re thrilled to have John join the Biote team as we strengthen our focus on serving the men’s hormone replacement therapy market,” said Terry Weber, Biote Chief Executive Officer.

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

Retrieved on: 
Lunedì, Aprile 3, 2023
Par, Partnership, Senior, Posaconazole, Endo International, AG, OTC, Endo, Merck & Co., Merck Sharp & Dohme Federal Credit Union, Pharmaceutical industry, Merck

DUBLIN, April 3, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic (AG) version of Merck's Noxafil® (posaconazole) 200 mg/5 mL oral suspension in the U.S.

Key Points: 
  • DUBLIN, April 3, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic (AG) version of Merck's Noxafil® (posaconazole) 200 mg/5 mL oral suspension in the U.S.
    "Our partnership with Merck underscores our reputation as an industry-leading supplier," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo.
  • "This newly available Noxafil® AG dosage form is the latest addition to our generics portfolio—providing patient access to high-quality, lower-cost treatment options."
  • Endo subsidiary Endo Ventures Limited entered into an exclusive U.S. supply and distribution agreement with a subsidiary of Merck & Co., Inc. of Rahway, N.J. allowing Par to launch and distribute an authorized generic version of the product.
  • The agreement also included the authorized generic version of Noxafil® delayed-release tablets, 100 mg, which launched in 2019.

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

Retrieved on: 
Lunedì, Aprile 3, 2023
Par, Partnership, Senior, Posaconazole, Endo International, AG, OTC, Endo, Merck & Co., Merck Sharp & Dohme Federal Credit Union, Pharmaceutical industry, Merck

DUBLIN, April 3, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic (AG) version of Merck's Noxafil® (posaconazole) 200 mg/5 mL oral suspension in the U.S.

Key Points: 
  • DUBLIN, April 3, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic (AG) version of Merck's Noxafil® (posaconazole) 200 mg/5 mL oral suspension in the U.S.
    "Our partnership with Merck underscores our reputation as an industry-leading supplier," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo.
  • "This newly available Noxafil® AG dosage form is the latest addition to our generics portfolio—providing patient access to high-quality, lower-cost treatment options."
  • Endo subsidiary Endo Ventures Limited entered into an exclusive U.S. supply and distribution agreement with a subsidiary of Merck & Co., Inc. of Rahway, N.J. allowing Par to launch and distribute an authorized generic version of the product.
  • The agreement also included the authorized generic version of Noxafil® delayed-release tablets, 100 mg, which launched in 2019.

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis

Retrieved on: 
Lunedì, Marzo 13, 2023
CCH, OTC, Patient, Trial of the century, Hardness, Fibromatosis, FFI, Endo, Endo International, Safety, Collagenase clostridium histolyticum, Medical imaging, Pharmaceutical industry

DUBLIN, March 13, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today announced top-line results from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in participants with plantar fibromatosis.

Key Points: 
  • DUBLIN, March 13, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today announced top-line results from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in participants with plantar fibromatosis.
  • The primary endpoint was improvement from baseline in the Foot Function Index (FFI) Pain Scale score when compared to those receiving placebo.
  • The CCH safety profile in the Phase 2 clinical study was consistent with the known CCH safety profile from other studies.
  • "The Phase 2 clinical study data will help us refine our Phase 3 clinical study design, and we plan to begin the pivotal program later this year.

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis

Retrieved on: 
Lunedì, Marzo 13, 2023
CCH, OTC, Patient, Trial of the century, Hardness, Fibromatosis, FFI, Endo, Endo International, Safety, Collagenase clostridium histolyticum, Medical imaging, Pharmaceutical industry

DUBLIN, March 13, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today announced top-line results from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in participants with plantar fibromatosis.

Key Points: 
  • DUBLIN, March 13, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today announced top-line results from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in participants with plantar fibromatosis.
  • The primary endpoint was improvement from baseline in the Foot Function Index (FFI) Pain Scale score when compared to those receiving placebo.
  • The CCH safety profile in the Phase 2 clinical study was consistent with the known CCH safety profile from other studies.
  • "The Phase 2 clinical study data will help us refine our Phase 3 clinical study design, and we plan to begin the pivotal program later this year.

Lazard Ltd Reports Full-Year and Fourth-Quarter 2022 Results

Retrieved on: 
Giovedì, Febbraio 2, 2023
Professional Services, Finance, BlackRock, Asset management, Terminix, EnCap Investments, House, Rentokil Initial, Liberty Global, Bain Capital, Telefónica, AUM, TA Associates, Veritas Capital, Tenneco, Tax, Acquisition, OCS, Infravia Capital Partners, Capital, GAAP, Sale, CD&R, Brazos Electric Power Cooperative, Placement, Service provider, Lazard, Bed Bath & Beyond, Endo International, Capital market, Share repurchase, R, Conference, H.I.G. Capital, Virgin Media, Centuri, Video game, Financial services, Cryptocurrency, Security (finance), Havea Tuʻihaʻangana

For the fourth quarter of 2022, Financial Advisory operating revenue was $404 million, 34% lower than the fourth quarter of 2021.

Key Points: 
  • For the fourth quarter of 2022, Financial Advisory operating revenue was $404 million, 34% lower than the fourth quarter of 2021.
  • AUM as of December 31, 2022 was $216 billion, down 21% from December 31, 2021, and 9% higher than September 30, 2022.
  • The provision for taxes, on an adjusted basis1, was $133 million for full-year 2022 and $24 million for the fourth quarter of 2022.
  • ET on February 2, 2023, to discuss the company’s financial results for the full year and fourth quarter of 2022.

Endo Launches "Man With a Plan" Campaign to Support Men With Symptoms of Peyronie's Disease

Retrieved on: 
Lunedì, Febbraio 6, 2023
Embarrassment, Confusion, Penis, India Reloaded: Inside India's Resurgent Consumer Market, PD, Commercial, Diagnosis, Empathy, Patient, Research, Health, Fear, Endo, Loneliness, Endo International, Peyronie's disease, Plan, Consumer, OTC, History, Pharmaceutical industry

DUBLIN, Feb. 6, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today the launch of the "Man With a Plan" campaign, which aims to motivate men who may have symptoms of Peyronie's disease (PD) to go to MakeaPDplan.com to find a specialized urologist who can diagnose and treat them. PD is a men's health condition that is estimated to affect 1 in 10 men in the U.S.* and can lead to a curvature deformity of the penis when erect.

Key Points: 
  • "The campaign speaks directly to internal agonizers—those men who are searching online and have unanswered questions about PD," said Gregory Thomas, Senior Director, Men's Health Marketing at Endo.
  • "With understanding and empathy, we're sending a clear message: Make a plan to talk to a specialized urologist."
  • "Endo's own market research confirms that the journey to treatment for men with PD can take years," added Dayna Sracic, Senior Director, Consumer Marketing at Endo.
  • * Based on a survey of about 7,700 U.S. adult men with a PD diagnosis, PD-related symptoms or a history of seeking treatment for the condition.

Endo Launches "Man With a Plan" Campaign to Support Men With Symptoms of Peyronie's Disease

Retrieved on: 
Lunedì, Febbraio 6, 2023
Embarrassment, Confusion, Penis, India Reloaded: Inside India's Resurgent Consumer Market, PD, Commercial, Diagnosis, Empathy, Patient, Research, Health, Fear, Endo, Loneliness, Endo International, Peyronie's disease, Plan, Consumer, OTC, History, Pharmaceutical industry

DUBLIN, Feb. 6, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today the launch of the "Man With a Plan" campaign, which aims to motivate men who may have symptoms of Peyronie's disease (PD) to go to MakeaPDplan.com to find a specialized urologist who can diagnose and treat them. PD is a men's health condition that is estimated to affect 1 in 10 men in the U.S.* and can lead to a curvature deformity of the penis when erect.

Key Points: 
  • "The campaign speaks directly to internal agonizers—those men who are searching online and have unanswered questions about PD," said Gregory Thomas, Senior Director, Men's Health Marketing at Endo.
  • "With understanding and empathy, we're sending a clear message: Make a plan to talk to a specialized urologist."
  • "Endo's own market research confirms that the journey to treatment for men with PD can take years," added Dayna Sracic, Senior Director, Consumer Marketing at Endo.
  • * Based on a survey of about 7,700 U.S. adult men with a PD diagnosis, PD-related symptoms or a history of seeking treatment for the condition.